The size and morphology of organs are largely determined by a genetic program. However in some cases, an epigenetic mechanism influences the process of organ development. Particularly, epigenetic factors such as hemodynamic stress and blood pressure affect the morphogenesis of cardiac chambers and valves. Here, we report that the epigenetic influences affect the cardiomyocyte production. Taking advantage of longer developmental period of medaka fish, we could examine the later emerging tissue responses to the defect of ventricular beating, which occurred in the hozuki (hoz) mutant that harbors the mutated ventricular myosin heavy chain (vmhc) gene. The mutant showed a remarkable ventricular enlargement, and we showed that this enlargement was due to an excess production of ventricular cardiomyocytes in addition to the lack of concentric chamber growth. By experimental blockade of blood flow, we demonstrated that an elevated cardiac pressure was responsible for the aberrant cardiomyocyte production. From these data, we propose that the epigenetic tissue response to a stressed situation controls the production of cardiomyocytes to attain a fine tuning of heart formation.
Introduction
The formation of a functional vertebrate heart requires processes that create proper morphology and size during embryonic development. In particular, an adequate size and wall thickness of the heart chambers are necessary for generating enough blood circulation for the growth of the animal. For this, the heart increases its cell number by cardiomyocyte proliferation, thickens the wall of its chambers by the concentric growth in a direction perpendicular to the lumen, and finally forms the highly trabeculated chambers. However, as the cardiomyocyte proliferation ceases after embryonic development, the postnatal increase in heart size occurs by the hypertrophic growth of individual cardiomyocytes, the increase in the amount of intercellular matrices, and the proliferation of non-muscle cells (Leu et al., 2001) . Only recently, it was reported that a fraction of adult cardiomyocytes retain the potential for cell division (Beltrami et al., 2001; Bergmann et al., 2009) , but the number of dividing cells is less than 0.0005% of total cardiomyocytes and less than 0.08% even when the heart is injured by infarcts (Soonpaa and Field, 1997) . Thus, the total number of cardiomyocytes, which is critical for the heart to function as a pump, is largely determined during embryonic development; and accordingly any subtle abnormalities in cardiomyocyte proliferation and heart morphogenesis in the embryo may affect the homeostasis and function of the postnatal heart.
A number of recent studies have suggested that both paracrine factors from peripheral tissues such as the epicardium and endocardium and autocrine factors secreted from the cardiomyocyte itself support cardiomyocyte proliferation and chamber morphogenesis. The action of retinoic acid (RA) and Erythropoietin (Epo) on epicardiac cells produces paracrine growth factors such as Fibroblast growth factors (Fgf) 9, 16, and 20; and the resultant activation of downstream signaling pathways through the FGF receptor induces the proliferation of myoblasts (Lavine et al., 2005) . In parallel, Bmp10 has been proposed as one of the autocrine growth factors expressed by the cardiomyocytes themselves. In Bmp10 knockout mice, an apparent reduction in cardiomyocyte proliferation occurs, accompanied by an increase in the level of P57Kip2, an inhibitory protein against Cyclin-dependent kinase (Cdk; Chen et al., 2004) . From the analysis of conditional knockout of the transcription factor Nkx2.5 in adult mice, it has been shown that Bmp10 function is also necessary for the trabecular muscle growth in postnatal stages (Pashmforoush et al., 2004) . Furthermore, additional signaling pathways including the Reptin and Pontin (Rottbauer et al., 2002) and the L-type calcium channel (Rottbauer et al., 2001) are also involved in the regulation of cardiomyocyte proliferation during development. In addition to these positive regulators, a study in mice has identified a negative regulator for cardiomyocyte proliferation, Jumonji, which is required for the cessation of cardiomyocyte proliferation in postnatal stages (Toyoda et al., 2003) . The Jumonji gene is expressed in stages when the active cardiomyocyte proliferation is terminated, and the mutant mice display an elevated expression of cyclinD1 and aberrant proliferation of their cardiomyocytes.
In addition to the cardiomyocyte number, another important process for making a functional heart is the formation of its thick-layered chambers. During the early stage of heart development, a thin-layered cardiac wall grows within a planar direction; however, at an appropriate stage of heart development, the cardiomyocyte changes the polarity of cell divisions and adds new cells in the myocardium in a direction perpendicular to the lumen to attain the concentric growth. Three zebrafish mutants with defective concentric growth of heart chambers, heart of glass, santa, and valentine, have been isolated by a mutant screening (Mably et al., 2003; Mably et al., 2006) . Analyses of them have identified a novel signaling pathway for concentric growth, in which the Heart of glass protein in the endocardium regulates the concentric growth of the myocardium. Additionally, the endocardium also plays a role in the trabeculation of the heart chambers; i.e., Neuregulin (Nrg), a molecule secreted from the endocardium, is necessary for the trabeculation by acting through its receptors, ErbB2 and ErbB4, in the myocardium (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995) .
Thus, cardiomyocyte proliferation and formation of a thick chamber wall are largely regulated by genetic factors. However, in addition to such genetic factors, recent studies have suggested that epigenetic factors also influence heart formation. For example, in the zebrafish mutant weak atrium (wea), which has a nonsense mutation in the atrium myosin heavy chain (amhc) gene, the ventricle formation is adversely affected due to the defective heartbeat in the atrium (Berdougo et al., 2003) . The silent heart (sih)/cardiac troponin T and cardiofunk (cfk)/sarcomere actin mutants, whose heartbeat is completely impaired, show a defect in endocardial cushion (EC) formation (Sehnert et al., 2002; Bartman et al., 2004) . Moreover, analysis using the wea and half-hearted (haf)/ventricle myosin heavy chain (vmhc) mutant zebrafish has suggested that the blood flow affects the regional cell-shape changes of cardiomyocytes and the resulting formation of the ventricular curvature (Auman et al., 2007) . Thus, epigenetic factors such as the heartbeat and blood flow influence heart morphogenesis. However, it has not been documented in detail whether or not the epigenetic factors also influence other aspects of heart morphogenesis such as the cardiomyocyte production and concentric chamber growth.
Here we report that the defective ventricular heart beat in the medaka mutant hozuki (hoz), which has a nonsense mutation in the vmhc gene, affected the concentric chamber growth and the number of cardiomyocytes in the ventricle. We show that an elevated cardiac pressure causes the excess production of cardiomyocyte. Our data thus suggest the existence of an epigenetic response mechanism that tunes the production of ventricular cardiomyocytes in response to an altered physiological condition.
Methods

Fish strains and maintenance
Medaka fish (Oryzias latipes) of wild type strains, Cab and HNI, were maintained at 28.5°C in a re-circulating system with a 14-h/day and 10-h/night cycle. The medaka heart mutant hozuki (hoz), a Japanese word meaning "ground cherry," was isolated by our previous mutant screening (Sakamoto et al., 2004) . Collected fertilized eggs were incubated at 28.5°C in medaka Ringer's solution (0.65% NaCl, 0.04% KCl, 0.011% CaCl 2 , 0.01% MgSO 4 , 0.01% NaHCO 3 , and 0.0001% methylene blue), and developmental stages were determined by their morphology according to the medaka stage table described by Iwamatsu (2004) .
Genetic mapping and positional cloning
Genetic mapping was performed according to the method described earlier (Kimura et al., 2005) . Briefly, a hoz mutant on the cab genetic background was crossed with the HNI strain to obtain the genetically polymorphic F1 offspring. These F1 fish were crossed to obtain the hoz mutant embryos for mapping. The pooled bulked segregant analysis was performed to localize the hoz mutation on the medaka linkage group (LG) (Postlethwait and Talbot, 1997) . Further mapping was done by using custom-designed markers based on the sequence polymorphism between the cab and HNI strains. The following mapping primers and restriction enzymes were used for mapping:
The coding sequence of vmhc cDNA was deposited in the GenBank/DDBJ DNA sequence database under an accession number AB515306.
Whole-mount RNA in situ hybridization (ISH) analysis
Whole-mount ISH analysis was performed according to the procedure described previously (Thisse and Thisse, 2008) . After staining, tissues were fixed with 4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS) for color preservation, equilibrated with 80% glycerol, and mounted on slide glasses for microscopic observation. The following primers were used for cloning the respective probes:
vmhc F: 5′-GCTGAGATGTCCGTGTATGGTGC-3′, R: 5′-GCTCCTCAC-GAGGCCTCTGCTTG-3′; mhc2 F: 5′-TCAGATCACACGGATTATGG-3′, R: 5′-ATGGCAGAGGGG-TATCCACC-3′; amhc F: 5′-TGCACTGATGGCTGAATTTG-3′, R: 5′-ACTTGATCTA-CACCTTGGCC-3′; cmlc2 F: 5′-AATGTCTTTTCCATGTTTGAGC-3′; R: 5′-CTCCTCTTTCTC-ATCCCCATG-3′; nkx2.5 F: 5′-CCAGCACGTCCACTCCTTTC-3′, R: 5′-TCACCACGTCC-TAATGCCG-3′; bmp10a F: 5′-CATCCGCAGCTTTAAGAACG-3′, R: 5′-TACAGCAGG-GAGATGGGGTC-3′; bmp10b F: 5′-TCATGCTGGAGCTCTACAATCG-3′, R:5′-CGCATTC-TGCTACTACCATTCC-3′; bnp F: 5′-CACAACAGACCGGAACCAGAACC-3′, R: 5′-GGGACGATC-TGGACAGTGGG-3′; jarid2/jumonji F: 5′-CCAACACAAATGCATTTACAAGG-3′, R: CGTAG-CGAGCAGAAGAGAGC-3′; tsc2 F: 5′-TACCAGCCGAGCAATGAGG-3′, R: GCCAGGTCCTTGTCTT-CAGC-3′; epo F: 5′-GCTGTTGATTGTGTTGGAGTGG-3′, R: CGCAGGAAGTT-CACGTGG-3′; nrg1 F: 5′-GAATTTACTGGTGATCGCTGCC-3′, R: AAAGCGACTGACGG-GACG-3′.
The respective products amplified by the polymerase chain reaction (PCR) were subcloned into standard vectors and used for synthesizing the digoxigenin (dig)-labeled RNA probes.
Electron microscopy and histology
Transmission electron microscopy (TEM) analysis was performed according to the method described earlier (Rottbauer et al., 2001) . The paraffin embedding and sectioning were performed according to a standard method using Bouin's fixative. Embedded samples were serially sectioned with a microtome; and the sections were mounted on slide glasses, washed with xylene and ethanol, and stained with hematoxylin and eosin.
Immunohistochemistry
Medaka whole embryos or dissected hearts were fixed by the following procedures. For staining with MF20, an antibody against the myosin heavy chain (Developmental Studies of Hybridoma Bank), embryos were fixed with the IHC Zinc Fixative (BD Biosciences) at room temperature for 20 h. For staining β-catenin (C2206, Sigma), fixation was done with 80% methanol, 20% dimethylsulfoxide (DMSO) at room temperature for 2 h followed by dehydration with methanol at −30°C. For phalloidin (Invitrogen) staining of F-actin bundles, dissected hearts were fixed with 4% PFA in PBS for overnight at 4°C. Following fixation and removal of the egg chorion, samples were equilibrated with PBS containing 0.1% Triton X-100 (PBSTx) and further replaced with PBSTx containing 1% DMSO (PBSTxD). Samples were blocked with 2 mg/ml BSA and 5% serum in PBSTxD for 2 h at room temperature and reacted with the above antibodies at 4°C for overnight. The MF20, anti-β-catenin, and Alexa568-conjugated phalloidin were used at 1:100, 1:1500, and 1:1000 dilutions, respectively. After washing with PBSTxD, the respective secondary antibodies were applied at room temperature for 2 h at 1:1000 dilutions. After washing, samples were mounted in 80% glycerol supplemented with 2.5% 1,4-diazabicyclo [2,2,2] octan (DABCO) as an antifade agent and viewed under a confocal microscope, Fluoview FV1000 (Olympus).
Measurement of ventricle size and the estimation of surface area
The lengths of long (L) and short (S) axes of wild type and hoz mutant ventricles at stage 37 were measured from confocal pictures of fixed and dissected hearts. We approximated the ventricle shape as a spheroid, and the surface areas were calculated from the following equation:
Incomplete elliptic integral of the 1st kind, F x; k
, and c are the major and minor axes of the spheroid; and in this case, a = L / 2 and b = c = S / 2.
BrdU analysis
The cell proliferation analysis was conducted after labeling embryos with BrdU for 20 h starting at stage 34. After incubation in 2 mM BrdU at 28.5°C, embryos were fixed with 4% PFA for 2 h at room temperature. The fixed embryos were dehydrated with methanol and stored at −20°C. Immunochemical detection was conducted by the procedure described recently (Yoshinari et al., 2009 ). The BrdU-labeled fluorescent cells were quantified from the acquired images obtained by a confocal microscopy (Fluoview FV1000, OLYMPUS). We routinely dissected the heart, mounted in an orientation that the ventricle and atrium boundary is clearly visible. More than 100 optical sections were obtained from each heart, and generate the partially stacked images by merging every 20-40 sections. Cell count was carefully performed on these optical slices to exclude the BrdU-labeled cells in non-muscle tissues.
Generation of transgenic fish and cell count
The construct that drives the expression of DsRed2-nuc under the control of the zebrafish cmlc2 promoter was a gift from G. C. Burns (Mably et al., 2003) . This construct was injected into fertilized medaka eggs at the 1-cell stage at a dose of 10-40 ng/μl. Embryos with bright fluorescence in the heart were raised, and a stable germ line transmission was established. The resulting transgenic strain was used for scoring the cardiomyocyte numbers in the ventricle. The wild type and hoz mutant hearts carrying the Tg (cmlc: DsRed2-nuc) were dissected, fixed with 4% PFA in PBS for 10 min at room temperature, and mounted in 1% agarose gel. We routinely made 50-100 optical sections from one heart sample, and cell count was conducted on the merged images of every 25 sections.
2,3-butanedione monoxime (2,3-BDM) treatment
We tested a series of 2,3-BDM concentrations on medaka fish at stage 32. Concentrations higher than 30 μM showed a toxic effect within 24 h; however at concentrations lower than 15 μM, the reagent could not effectively block the heartbeat. For the healthy survival of medaka fish and complete block of heartbeat, we adopted the 2,3-BDM treatment at 22.5 μM for 24 h and 17.5 μM for the following 48 h. Under this condition, the ventricle did not beat, but the atrium showed an occasional and weak beating. In some wild type embryos, the accumulation of blood cells in the atrium was observed, but it did not affect the number of ventricular cardiomyocytes.
RT-PCR analysis
Hearts were harvested from wild type and hoz mutant embryos (n = 40 for each) at stage 37. Total RNAs were extracted and 5 μg of total RNA was used for cDNA synthesis. The primers for bnf and bmp10 were the same as those used for cloning the in situ probes. ef1α was amplified with primers: F, 5′-ATCGTTGCTGCTGGTGTTG-3′; R, 5′-AGGCGATGTGAGCTGTGTG-3′, as an internal control. The PCR reaction comprised 94°C for 30 s, 55°C for 30 s, and 72°C for 30 min.
Results
Enlarged ventricle in the medaka hoz mutant
In the previous screening for ENU-induced mutations of medaka fish, we identified several mutants with phenotypes showing abnormal heart development. The hoz mutant was a recessive lethal mutant having an abnormally large ventricle. Initial formation of the hoz heart tube appeared to be normal until medaka developmental stage 30, a stage that corresponds to the cardiac looping stage (Fig. 1C ). However in the subsequent stages of development, their ventricles progressively enlarged (Figs. 1A, B ). Despite this abnormality, the mutant survived until 8 dpf, a stage around hatching, in a relatively healthy condition without forming pericardiac edemas.
Observations of the hoz ventricle showed that ventricular contraction was inhibited when the ventricle and atrium are segregated at stage 26 (see Supplementary Videos 1 and 2). The blood flow was clogged in the ventricle due to the sustained beating of the atrium, although a very slow stream of blood flow could be seen at stage 37 (data not shown). It is therefore believed that ventricular enlargement was a secondary defect due to heart malfunction. In spite of the defect of blood flow, the overall number of blood cells appeared similar between wild type and mutant embryos during stages 30-39 (data not shown), suggesting that the overall hematopoiesis was not affected in the hoz mutant. Furthermore, the beat rate of the hoz atrium did not show significant alteration at stage 37 (Table 1) , a stage when the enlargement of the hoz ventricle became maximum. In comparison to the ventricle, the size of the hoz atrium was never affected (Fig. 1B) .
Comparing with similar zebrafish heart mutants with defective beating (Sehnert et al., 2002; Berdougo et al. 2003; Bartman et al., 2004; Auman et al., 2007; Rottbauer et al., 2006) , which have been mainly analyzed within 48 hpf of zebrafish development (highlighted with green in Fig. 1C ), the hoz mutant showed a characteristic enlargement of the ventricle at later stages of heart development (highlighted with pink in Fig. 1C ). Thus, the hoz mutant has a unique later heart phenotype that occurs late in development, likely due to secondary defects caused by the abnormal ventricular contractions.
Loss-of-function mutation in the ventricle myosin heavy chain (mhc1/vmhc) gene in the hoz mutant
To explore the molecular basis of the hoz mutant, we determined the responsible gene. Genetic mapping localized the hoz locus to medaka linkage group 17, a region located between ZPC2 and MF01SSA041A11 ( Fig. 2A) . By further fine mapping, we identified a genomic sequence contig of approximately 250 kb length, the entire region of which showed zero recombination with the hoz locus ( Fig. 2A ). The contig contained 4 myosin heavy chain (mhc) genes, one of which had a strong sequence homology with the vmhc gene of zebrafish and other species.
To further narrow down the candidates, we examined the expression of all 5 genes on the contig by in situ RNA hybridization and found that only the vmhc-like gene (mhc1 in Fig. 2A ) , but not other 4 genes, had an exclusive expression in the ventricle (Fig. 2B ), suggesting the mhc1/vmhc gene was most likely to be the hoz gene. The second gene mhc2, which corresponded to the mMYHC1 gene reported by Ono et al. (2006) (GenBank AB256934), was expressed in the slow skeletal muscle of the somites (data not shown).
Given the unique expression of mhc1/vmhc gene in the ventricle, we focused on this gene and performed further analysis. The sequence Fig. 1 . Ventricle enlargement of the medaka hoz mutant. (A, B) Morphology of wild type and hoz mutant heart at stage 37. The mutant showed a unique phenotype that the ventricle (V) was extraordinary enlarged and filled with blood cells (panel B) , whereas the mutant atrium (A) had a normal appearance (panel A). Due to inability of heart beating in the ventricle (see Videos S1, S2 in the supplementary material), the blood flow was very slow and almost clogged around stage 34. (C) A diagram comparing developmental stages of medaka fish and zebrafish. The medaka developmental stages (top) and the corresponding zebrafish stages are aligned (bottom), in which the key events of heart morphogenesis are indicated in the middle. Though the zebrafish heart mutants with defective beating (Sehnert et al., 2002; Berdougo et al. 2003; Bartman et al., 2004; Auman et al., 2007; Rottbauer et al., 2007) have been mainly analyzed within 48 hpf (highlighted with green), the hoz mutant showed a characteristic ventricle enlargement phenotype at the later stage of heart development (highlighted with pink), which was possibly due to its longer survival until 8 dpf in a relatively healthy condition without the formation of pericardiac edemas. The scale bar represents 100 μm in (A).
Table 1
Heart beating rate of wild type embryos and hoz mutant.
Heartbeat at stage 30 n Heartbeat at stage 37 n Wild type 137 ± 5 7 157 ± 4 4 hoz mutant 136 ± 5 7 152 ± 2 4
Quantitative analysis of heart beating (per minute) at stage 30 and stage 37 at 28.5°C is shown. Measurement was performed by using the recorded movies. The rate in hoz mutant was measured by the atrial beating.
analysis revealed that the vmhc gene had a nonsense mutation at the middle of its protein-coding region (Fig. 2C) , resulting in the loss of most of the myosin tail domain, which is necessary for the assembly of myosin heavy chains to form their coiled-coil structure (Fig. 2D ). Intriguingly, we found that the expression of mhc1/vmhc was severely down-regulated in the hoz mutant ( Fig. 2B) , possibly due to the mechanism known as nonsense-mediated RNA decay. We also confirmed that the hoz ventricle did not contain the Mhc proteins by staining with the pan-myosin heavy chain antibody, MF20 ( Fig. 2E ), supporting that there was no compensatory expression of other myosin heavy chains in the ventricle and that the identified mutation in the mhc1/vmhc is the cause of loss of ventricle beating. Although we could neither succeed in producing the phenocopy by the morpholino antisense oligonucleotide (MO) nor rescue the hoz phenotype with mRNA injection due to the late hoz phonotype (3-4 dpf), from these supporting evidences, we concluded that the hoz mutation resulted in the complete loss of myosin heavy chain function in the ventricle.
Effect of vmhc mutation on cardiomyocyte differentiation and maturation
We next examined how the heart formation and maturation is affected by the loss of Vmhc function and heart contraction. We evaluated the cardiomyocyte differentiation in the hoz mutant by looking at the expression of genes such as nkx2.5, tbx5, and mef2c (Olson, 2006) , transcription factors whose products are required for heart development and cardiomyocyte differentiation. However, no significant alteration of their gene expression was observed in the hoz heart primordium ( Supplementary Figs. 1A-C ), suggesting that the heart-field formation and cardiomyocyte differentiation occurred normally in the hoz mutant. As well as the regulatory transcription factors, the expression of cmlc2 and amhc, genes encoding the myofibril proteins in the entire heart and atrium, respectively, were neither affected in the hoz mutant ( Supplementary Figs. 1D, E) .
Given the normal differentiation of ventricular cardiomyocytes, we next asked whether or not they matured normally as cardiac muscle cells. To examine the maturation status of ventricular myocytes, we examined their subcellular structures by electron microscopy analysis. In contrast to the thick myofibrils seen in the wild type ventricular cells (see arrow in Fig. 3A) , the hoz ventricular cells lacked the myofibrils and contractile apparatus (Fig. 3B ). However, despite the lack of myofibrils, the mutant ventricular cells retained a number of mitochondria as in the wild type cardiomyocytes (Figs. 3A,  B ; arrowheads) and stored a number of dense glycogen particles in their cytoplasm (Fig. 3B ), suggesting that the cardiomyocyte maturation process somehow occurred in the hoz ventricle. On the other hand, we did not see any abnormalities in the atrial myocytes (data not shown).
Defective chamber morphogenesis in the hoz ventricle
A previous study by Auman et al. (2007) on zebrafish mutants with altered amhc and vmhc genes suggested that cardiac contractility and blood flow are required for proper cell-shape changes and the formation of chamber curvature during heart morphogenesis. In the hoz mutant, we visualized the cell shape by staining with anti-βcatenin antibody ( Supplementary Figs. 2A-D) and observed that the ventricular cardiomyocyte in the hoz mutant is also expanded within the planar dimension and have irregular but hexagonal shapes as in the zebrafish vmhc mutant (Auman et al., 2007 ; Supplementary  Fig. 2D ). In addition, the phalloidin staining showed that the formation of contractile F-actin cables, which are associated with myosin heavy chains, was missing in the hoz mutant ( Supplementary  Figs. 2E, F) , indicating that the loss of myosin heavy chain affects the formation of F-actin bundles.
In addition to such a phenotype in the cardiomyocyte cell shape, we found that the concentric chamber growth was also impaired. Following the stage of cardiac looping and the formation of curvature, the cardiac chambers increase thickness of the wall through the concentric growth, and give rise to the trabeculated chambers in the adult animal. The concentric growth of the ventricular wall begins in medaka fish at stage 34, when the wall thickness is 1-2 cell layers (Fig. 4A) . By stage 36, 3-4 layers of cardiomyocytes can be recognized (Fig. 4C ). In the hoz mutant, the ventricular wall was also 1-2 layers at stage 34 and remained so at stage 36 (Figs. 4B, D) , even after stage 37. To further confirm this phenotype, we utilized the Tg (cmlc2:DsRed2nuc) embryo, in which the identity of cardiomyocytes was visible by the expression of DsRed2 in the nucleus, and revealed that the lack of cardiomyocyte layers indeed occurred in the hoz mutant (Figs. 4E, F) . Thus, the loss of Vmhc function affected the concentric chamber growth in the later phase of heart development.
Excess production of cardiomyocytes in the hoz ventricle
As we have shown in Fig. 1B , the hoz ventricle was strikingly enlarged. We suspected that merely the cell-surface expansion and lack of concentric growth could not account for it. Indeed, according to our estimation (Fig. 5A) , the surface area of the hoz ventricle was approximately 6 times greater than that of the wild type one at stage 37 (Fig. 5B ). Taking the decrease of concentric growth in account, which increases the surface area by 2 times, there was still a 3-fold increase in the surface area. Judging from the spacing of cardiomyo-cyte nuclei (Figs. 4E, F) , the expansion of each cell surface may not be as big as 3 times. Therefore, we suspected that an increase in cell number might have been responsible for the ventricular enlargement.
We examined cell proliferation by labeling with BrdU during stages 34-36 ( Fig. 5C ). Though it has been suggested that the cardiomyocyte proliferation rate is relatively low before the heart looping stage in chick and zebrafish (Soufan et al., 2006; de Pater et al., 2009) , the rate after the looping stage (Fig. 1C ) appeared to be higher, possibly due to the rapid increase of the thickness of chamber wall. We indeed observed that a number of BrdU-labeled cells were present in the entire chamber wall region of the wild type heart by examining the confocal optical sections. Using the confocal images, we carefully counted the BrdU-labeled cells within the cardiomyocyte layers and revealed a detectable increase of the number of BrdU-positive cells (∼1.4 fold) in the hoz ventricle (Fig. 5D ), although the statistical significance was not sufficient (P b 0.1), which was probably due to the higher number of proliferating cardiomyocytes in this stage and inevitable count of the endocardium and blood cells.
To precisely determine the number of cardiomyocyte, we used the Tg (cmlc2:DsRed2-nuc), expressing DsRed in the cardiomyocyte nuclei (Figs. 5E, F). As in the BrdU analysis, we quantified the number of cardiomyocytes by using confocal images and found that the hoz mutant ventricle displayed a significant increase in the number of cardiomyocytes compared with the wild type ventricle at stage 34 and stage 37; whereas the difference was not evident at stage 30 ( Fig. 5F ). Such increase was more evident at stage 37 (wild type: 261 ± 20; hoz mutant: 413± 16). Therefore, the number of cardiomyocytes in the hoz ventricle increased more than 1.5 times than that of the wild type one. Since the number of cardiomyocytes in wild type embryos was 332± 20 (n = 4) even at stage 39, 2 days after stage 37, we concluded that an excess number of cardiomyocytes were added in the hoz ventricle during later phase of heart development. In contrast to the increase of ventricular cardiomyocyte, we did not see any detectable alterations in cardiomyocyte number, shape and size in the atrium, although we did not perform an accurate quantification.
Induction of bnp and bmp10 family gene expression in the hoz ventricle in response to the increased cardiac pressure
Progressive enlargement of the ventricle often accompanies elevated cardiac pressure. We therefore investigated whether the loss of ventricular beating caused a stress on the developing ventricle. To evaluate the stressed status of ventricle, we looked at the expression of natriuretic peptide genes. As a modulator of cardiac function, this family of proteins, which is induced in the hypertrophic and dilated cardiomyopathies of mammals, is known to be the most powerful neurohumoral predictor of left-ventricular function and prognosis (Cameron and Ellmers, 2003; Clerk et al., 2007) . Though the atrial natriuretic peptide (anp) gene is widely used as a marker for cardiac stress, medaka fish does not have an exact ortholog (Inoue et al., 2003 ; our database search). Instead, we used the brain natriuretic peptide (bnp) gene, which is also known to have similar functions and to be induced by physiological stresses (Tokola et al., 2001; Cameron and Ellmers, 2003) . The results of in situ expression and RT-PCR analysis showed that the expression of bnp was strongly elevated only in the ventricle (Figs. 5G, H) , confirming that the hoz ventricle was exposed to a stressed status.
We next examined the expression of molecules such as tsc2 (Pasumarthi et al., 2000) , epo (Stuckmann et al., 2003) , nrg1 (Ford et al., 1999) , jarid2/jumonji (Toyoda et al., 2003) , fgf2 (Sheikh et al., 1999) , raldh2 (Keegan et al., 2005; Wills et al., 2008) , and bmp10 that are implicated in the regulation of heart growth. Among them, only the expression of the bmp10a and bmp10b genes exhibited apparent up-regulation in the hoz ventricle (Figs. 5G,  H) , while bmp10a showed a weaker expression (data not shown). (A, B) Examination of subcellular structure of wild type (A) and mutant (B) ventricular cells at stage 37 by transmission electron microscopy. Thick myofiber bundles were seen in the cardiomyocytes of the wild type embryo (arrow), but not in those of the hoz mutant. Arrowheads indicate the well-developed mitochondria, a hallmark of mature cardiac muscles. Both in wild type and mutant, many glycogen granules, which are also a sign of mature cardiomyocytes, were present within the ventricular cardiomyocytes. A high-magnification view of glycogen granules (boxed area in B) is shown in the upper right corner. The observations were confirmed by examining more than 90 sections through the heart region from each of 3 wild type and 2 mutant embryos. n, nucleus. The scale bar represents 1 μm in (A).
Regulation of cardiomyocyte production and bmp10b induction by elevated cardiac pressure
It has been proposed that intracardiac hemodynamics and blood pressure act as a key epigenetic factor in embryonic cardiogenesis (Hove et al., 2003) . Therefore, we next examined whether or not the increase in cardiomyocyte number in the hoz mutant depended on the elevated cardiac pressure caused by the inability of ventricular beating. In order to dissect the effect of cardiac pressure, the morpholino antisense oligonucleotide against troponin T was successfully used to abolish the heartbeat in zebrafish (Sehnert et al., 2002) ; however it could not be applied to reduce the heart beating in medaka fish due to the long developmental period. In this study, we firstly adopted an approach to manipulate the blood flow without affecting myocardial function. In contrast to the zebrafish, the veins in medaka fish that flow into the sinus venosus (SV) are arranged into 3 major ducts, i.e., the 2 common cardinal veins (CCV) located laterally and the marginal vein (MV) from the caudal region ( Fig. 6A ; Fujita et al., 2006) . By firmly pinching and crushing these veins with forceps at stage 32, we succeeded in blocking the blood flow (Figs. 6B, C) .
Such an operation could reduced the blood inflow into the atrium; and the fluid between the ventricle and operated sites moved back and forth, resulting in the alleviation of excess blood pressure in the hoz mutant. In the hoz embryos in which blood flow was not present at stage 37 (3 of 7 operated embryos), the average number of cardiomyocytes (239 cells; Fig. 6E ) was comparable with that of operated wild type (255 cells, n = 2) ( Fig. 6D ) and un-operated wild type embryos (see Figs. 5E, F) . Moreover, embryos in which flow was partially blocked showed an intermediate phenotype (327 cells, n = 3). These data supports that the cardiomyocyte increase observed in the hoz mutant ventricle depended on the elevated cardiac pressure.
Because the mechanical blockade was not a perfectly successful method due to occasional recovery of crashed blood vessel, we further performed a pharmacological blockade of blood flow. In zebrafish, reagents such as 2,3-butanedione monoxime (2,3-BDM), which blocks myofibrillar ATPase, was used to reduce the heartbeat (Bartman et al., 2004; Auman et al., 2007) . In medaka embryo, the reagent affected the heartbeat at higher concentrations than that for zebrafish. At the condition we used, the ventricle was completely silent, but the atrium occasionally beat at a very slow rate in some embryos. Under this condition, almost all embryos survived in a healthy condition up to 3 days from stage 32 to 37 (Figs. 6F, G) . In the hoz embryos treated with 2,3-BDM, the morphology of the ventricle was apparently smaller than the untreated hoz ventricle and similar to that of wild type (Figs. 6F, G) . The number of cardiomyocytes was comparable with that of wild type embryos treated with the reagent (Figs. 6H-J) . Intriguingly, the lack of concentric growth in the hoz ventricle was also rescued by the decreased cardiac pressure (Figs. 6E, I ), suggesting . Paraffin sections were counter-stained with hematoxylin and eosin. The hoz ventricle was filled with blood cells, most of which were nucleated red blood cells (RBC). The concentric growth of the ventricular wall was not evident at stage 34 (A, B). But at stage 36, 3-4 cells layers were apparently observed (C), whereas the ventricular wall of the hoz mutant remained 1-2 layers at this stage (D). (E, F) Confocal optical sections of ventricular chambers of wild type (E) and hoz mutant (F) at stage 37, in which the cardiomyocytes were visualized by the Tg (cmlc2:DsRed2-nuc). The defect in concentric growth of cardiomyocyte layers is clearly observed in the hoz ventricle. The scale bar represents 50 μm in (A). All pictures are at the same magnification. Cell count was performed on the confocal images to exclude the labeling in non-muscle regions such as the blood cells and endocardial cells. Data are presented as the mean ± SEM. Statistical significance was tested by the use of Student's t-test. **P b 0.1 (n = 11 for wt, n = 9 for hoz). (E) Confocal stacked images of wild type and hoz mutant hearts that harbor the Tg (cmlc2:DsRed2-nuc) at stage 37. These pictures are reconstructed confocal images, in which approximately half of the cardiomyocytes are visible. (F) Quantification of ventricular cardiomyocytes using the transgenic line. Cell counting was performed on the confocal images. Data are presented as the mean ± SEM. Statistical significance was tested by using Student's t-test. NS, statistically not significant at P = 0.01 (n = 5 for WT and hoz, respectively). *P b 0.01 (n = 5 for WT and hoz, respectively, at stage 34; n = 7 for WT and n = 6 for hoz at stage 38). (G, H) Induction of bnp and bmp10b expression in response to the elevated cardiac pressure. In situ RNA hybridization analysis (G) detected the strong expression of brain natriuretic peptide (bnp) at stage 37 and bmp10b at stage 34 in the mutant ventricle (V), whereas only a faint expression was detected in wild type. RT-PCR analysis of the expression levels of bnp, bmp10b, ef1α, and amhc, in wild type (W) and hoz mutant (M) embryos at stage 37 (H) quantitatively supported the induction of bnp and bmp10b in the hoz heart. The number of PCR amplification cycle were 28 cycles for amhc and bnp, 27 cycles for bmp10b, and 23 cycles for ef1α. V, ventricle; A, atrium. The scale bar represents 50 μm in (C) and (E), and 100 μm in (G). that the ability for concentric growth is retained in the hoz ventricle and that the increased cardiac pressure impairs the proper chamber growth.
In spite of the rescue of hoz phenotypes, the 2,3-BDM treatment significantly reduced the cardiomyocyte proliferation in the wild type embryos (Fig. 6J ). This raises possibilities that the cardiac pressure is a necessary driving force to support the cardiomyocyte proliferation or that 2,3-BDM affected the cell proliferation by a side effect that is independent of the cardiac pressure. Considering the result of blood vessel operation and the healthy heart development including the concentric chamber growth in the presence of 2,3-BDM, the former possibility seems to be more plausible than the side effect of 2,3-BDM.
To further examine the causal relation between the cardiac pressure, cardiomyocyte increase, and the induction of bmp10, we looked at the expression of bmp10b in the embryos in which the cardiac pressure was lowered by the 2,3-BDM treatment (Figs. 6K, L) . The bmp10b expression was apparently reduced in embryos treated with 2,3-BDM ( Fig. 6L; n = 8) . The data supports that the bmp10 expression is under the regulation of the elevated cardiac pressure. Taken together, our results suggest that Bmp10, which has been suggested to promote the cardiomyocyte proliferation in mammals, may act as a mediator for the cardiomyocyte increase in the hoz mutant in response to the elevated cardiac pressure.
Discussion
The heart begins to function long before its formation is complete. It is known that cardiomyocytes are produced almost exclusively during development, and hence it has been thought that the number Fig. 6 . Influence of elevated cardiac pressure on cardiomyocyte proliferation. (A-C) Outline of the blood vessel blockage experiment. In medaka embryo at stage 32, the venous blood inflows into the sinus venosus (SV) through 3 major veins, i.e., the 2 common cardinal veins (CCV) and the marginal vein (MV), which run on the surface of the yolk (A) (Fujita et al., 2006) . By mechanically crushing these veins (arrowheads in A and B), the blood flow into the heart was blocked (C). (D, E) Visualization of cardiomyocytes in the operated embryos. Cardiomyocytes of wild type (D) and hoz mutant (E) embryos at stage 37 were visualized by the Tg (cmlc2:DsRed2-nuc). of cardiomyocytes is simply determined according to the genetic program. In this study, by analyzing the medaka vmhc mutant, hoz, we demonstrated that the cardiomyocyte number is influenced by elevated cardiac pressure presumably through the induction of Bmp10, a potent mitogenic factor for cardiomyocytes. Our results suggest the presence of a compensatory mechanism that modulates the production of cardiomyocyte in response to an altered physiological condition, which could also be at play in response to stressed conditions even in postnatal stages.
Later occurring increase of cardiomyocyte number in the hoz mutant
The analysis of zebrafish mutations has suggested a relationship of cardiomyocyte dysfunction and resulting hemodynamic stress and/or elevated cardiac pressure with heart morphogenesis (Sehnert et al., 2002; Xu et al., 2002; Berdougo et al., 2003; Rottbauer et al., 2006; Auman et al., 2007) . Though these mutations cause heart dilation, the number of cardiomyocytes has not been extensively addressed. Only for the haf mutant, in which the vmhc gene is disrupted, it has been reported that the number of cardiomyocytes was not altered (Auman et al., 2007) , which is in contrast with our analysis of the medaka vmhc mutant, hoz. The reason for this difference may be due to the stages analyzed. In zebrafish, the heart looping is completed at 2 days post fertilization (dpf), whereas the looping occurs at 3 dpf in medaka fish among the 8-9 days of embryonic development (Fig. 1C) . Though the number of cardiomyocytes in the haf mutant was counted at 2 dpf (Auman et al., 2007) , we did not see any difference between wild type and hoz embryos at the corresponding medaka stage 30 (Fig. 5F) . The difference became apparent only in the successive stages. Furthermore, as the hoz mutant can survive more than 5 days after stage 30, the slow development and longer progression of the phenotype could make the phenotype clear in medaka fish.
Cell-surface extension and cell-shape abnormality in the hoz mutant
On the other hand, a similar phenotype to the zebrafish haf mutant was also observed in cell-shape and surface-area extension (Supplementary Fig. 2D ). Though we did not analyze the detail of this phenotype, it seemed that the surface area was slightly extended in the mutant cardiomyocytes. Considering the 1.6-fold increase in cardiomyocyte proliferation and 2-fold increase of the number of surface cells due to the lack of concentric growth, the surface-area extension of each cardiomyocyte would be expected to be 1.75-fold in the hoz mutant for attaining the 5.6-fold increase in the total ventricular surface area. This calculation corresponds to the measured cell-surface extension, 1.8-times, found in the zebrafish haf mutant (Auman et al., 2007) , suggesting that a similar extent of cell-surface extension occurs in the hoz mutant.
Concentric growth of cardiac chambers
Another phenotype that we found in the medaka hoz mutant was the lack of concentric chamber growth of the ventricle. It has been suggested that a signal emanating from the endocardium regulates the concentric chamber growth (Mably et al., 2006) . Within cardiomyocytes, the cardiomyocyte cell polarity such as the oriented formation of myofibers plays an important role in heart morphogenesis and concentric chamber growth (Sultana et al., 2008) . Moreover, an intrinsic signaling mechanism that associates with the contractile machinery and/or signaling scaffold such as the Titin complex might also be involved in the concentric growth of chamber (Granzier and Labeit, 2005; Linke, 2008) . Therefore, a proper heartbeat, sarcomere function and/or orientation could be required for mediating the signal to direct the dimension of chamber growth.
However, our experiments blocking the blood flow suggested that the hoz ventricle retains the ability for the concentric growth and that it can perform a considerable extent of concentric growth when the cardiac pressure was decreased. This suggests that the concentric growth can occur in the absence of the myofiber and heart beating. Possibly, the concentric growth in the hoz mutant may be suppressed by the improper cell polarity caused by a strong mechanical overload toward the planar direction and/or the shortage of cardiomyocyte supply to sufficiently support the increase of chamber growth.
Another interesting phenotype of hoz mutant was that the lack of contractile apparatus and inability of ventricular beating did not affect the cardiomyocyte maturation itself, suggesting that the cardiomyocyte maturation is independent from the heart beating and elevated cardiac pressure. The cardiomyocyte maturation as a muscle cell might be regulated by other factors such as the Nkx2.5, Tbx5, and Mef2c, which control cell differentiation. Consistent with this idea, the expression of these genes was not affected in the hoz mutant.
Epigenetic regulation of cardiomyocyte number in response to elevated cardiac pressure An important implication made from our analysis is that cardiomyocyte production during development is determined not only by genetic program, but also by epigenetic conditions. The number of cardiomyocytes increased as much as 1.6-fold by the increased blood pressure. Such a fluctuation in cardiomyocyte number generated during development may affect the heart function throughout the life of an animal (Leu et al., 2001) . Thus, we suggested that the cardiomyocyte proliferation in response to epigenetic influences is a major cause of increased cardiomyocytes; however, it has recently been proposed in zebrafish as well as amniotes that cardiomyocytes differentiate from the second heart field (SHF) to support the cardiomyocyte number increases during cardiac looping (de Pater et al., 2009) . So, there is a possibility that the number of cell in the ventricle increases by recruitment and differentiation of cells from the SHF. However, our quantification of cell proliferation at stage 34-35 showed 1.4-fold increase of BrdU-positive cardiomyocytes, which is comparable to the actual increase of cardiomyocytes (stage 34, 1.3 fold; stage 38, 1.6-fold) revealed by the Tg (cmlc2:DsRed2-nuc). In addition, the ventricle enlargement in the hoz becomes apparent after the heart looping. Therefore, it is likely that the observed cardiomyocyte increase in the hoz mutant may mainly reflect the cell proliferation within the ventricle.
Importantly, we observed that Bmp10 was induced in the hoz ventricle. Though we do not have a direct functional test of medaka Bmp10, the BMP10 function for cardiomyocyte proliferation has been well documented in mammals Pashmforoush et al., 2004) . More recently, up-regulation of Bmp10 expression in the hypertrophic rat heart has been observed, and its implication in adaptive myocardial hypertrophy has been made (Nakano et al., 2007) . From these and other studies in mammals, it is highly probable that Bmp10 has a function in supporting excess cardiomyocyte proliferation of the hoz mutant. Other than Bmp10, a number of other proteins such as the Reptin and Pontin (Rottbauer et al., 2002) , L-type calcium channel (Rottbauer et al., 2001) , and PDGF (Lien et al., 2006) also have functions for controlling cardiomyocyte proliferation. However, since Bmp10 is the only molecule whose expression was induced in the hoz mutant, the Bmp10 expression in response to stressed conditions may play a compensatory role that tunes the heart formation. Hence, any mis-regulation of the mechanism during development could lead to congenital heart disorders (Bartman et al., 2004) , and it could also affect the cardiomyocyte proliferation (Bergmann et al., 2009) and hypertrophic growth in cardiomyopathies (Akazawa and Komuro, 2003; Oka et al., 2007; Ransom and Srivastava, 2007) even in the postnatal periods.
Considering the function of Bmp10 protein in promoting cardiomyocyte proliferation , induction of bmp10 in response to increased blood pressure may explain the aberrant production of cardiomyocytes in the hoz ventricle.
